TN2016000259A1 - Salbutamol (albuterol) eye protective medicament. - Google Patents
Salbutamol (albuterol) eye protective medicament.Info
- Publication number
- TN2016000259A1 TN2016000259A1 TN2016000259A TN2016000259A TN2016000259A1 TN 2016000259 A1 TN2016000259 A1 TN 2016000259A1 TN 2016000259 A TN2016000259 A TN 2016000259A TN 2016000259 A TN2016000259 A TN 2016000259A TN 2016000259 A1 TN2016000259 A1 TN 2016000259A1
- Authority
- TN
- Tunisia
- Prior art keywords
- salbutamol
- albuterol
- medicament
- eye
- eye protective
- Prior art date
Links
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002052 salbutamol Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 230000001681 protective effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000007423 decrease Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000002287 Keratoconus Diseases 0.000 abstract 1
- 208000003435 Optic Neuritis Diseases 0.000 abstract 1
- 208000029091 Refraction disease Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 230000004430 ametropia Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229960001089 dobutamine Drugs 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000004438 eyesight Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000010041 presbyopia Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000014733 refractive error Diseases 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 230000004382 visual function Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TN2016000259A TN2016000259A1 (en) | 2016-06-27 | 2016-06-27 | Salbutamol (albuterol) eye protective medicament. |
| MA045457A MA45457A (fr) | 2016-06-27 | 2017-06-27 | Médicament ophtalmique contenant du salbutamol. |
| CN201780052188.6A CN110114066B (zh) | 2016-06-27 | 2017-06-27 | 含沙丁胺醇的眼科药物 |
| JP2018568424A JP7176960B2 (ja) | 2016-06-27 | 2017-06-27 | サルブタモール含有眼科用医薬 |
| PCT/IB2017/000779 WO2018007864A1 (en) | 2016-06-27 | 2017-06-27 | Salbutamol-containing ophthalmic medicament |
| RU2018146575A RU2774971C2 (ru) | 2016-06-27 | 2017-06-27 | Офтальмологическое лекарственное средство, содержащее сальбутамол |
| US16/313,425 US11484513B2 (en) | 2016-06-27 | 2017-06-27 | Salbutamol-containing ophthalmic medicament |
| CA3028924A CA3028924C (en) | 2016-06-27 | 2017-06-27 | Salbutamol-containing ophthalmic medicament |
| EP17745488.1A EP3474836B1 (en) | 2016-06-27 | 2017-06-27 | Salbutamol-containing ophthalmic medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TN2016000259A TN2016000259A1 (en) | 2016-06-27 | 2016-06-27 | Salbutamol (albuterol) eye protective medicament. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2016000259A1 true TN2016000259A1 (en) | 2017-10-06 |
Family
ID=59416735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2016000259A TN2016000259A1 (en) | 2016-06-27 | 2016-06-27 | Salbutamol (albuterol) eye protective medicament. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11484513B2 (enExample) |
| EP (1) | EP3474836B1 (enExample) |
| JP (1) | JP7176960B2 (enExample) |
| CN (1) | CN110114066B (enExample) |
| MA (1) | MA45457A (enExample) |
| TN (1) | TN2016000259A1 (enExample) |
| WO (1) | WO2018007864A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119097618A (zh) * | 2019-03-02 | 2024-12-10 | 内在生物技术有限公司 | 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 |
| KR20220018484A (ko) * | 2019-06-10 | 2022-02-15 | 제니비젼 인크. | 시력 장애를 치료하기 위한 방법 및 제형 |
| MD3989962T2 (ro) | 2019-06-28 | 2025-12-31 | Intrabio Ltd Gb | Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală |
| JP7066293B2 (ja) * | 2019-11-12 | 2022-05-13 | 株式会社ファンケル | サーチュイン１（ｓｉｒｔ１）発現増強用組成物 |
| WO2021144720A1 (en) | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| KR20230015433A (ko) * | 2020-05-22 | 2023-01-31 | 인트라바이오 리미티드 | 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물 |
| EP4694929A1 (en) * | 2023-04-08 | 2026-02-18 | Sung-Jan Lin | Methods for treating corneal injuries |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985897A (en) * | 1973-12-21 | 1976-10-12 | Mead Johnson & Company | Ocular hypotensive process employing dextrorotatory sulfonamidophenethanolamines |
| SE8701258D0 (sv) * | 1987-03-26 | 1987-03-26 | Pharmacia Ab | A composition for the topical treatment of glaucoma or ocular hypertension |
| US5192780A (en) * | 1989-12-18 | 1993-03-09 | Alcon Laboratories, Inc. | Methods using antiallergics and antihistamines |
| US6569903B2 (en) * | 1999-12-07 | 2003-05-27 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic compositions |
| WO2003049745A1 (en) | 2001-12-12 | 2003-06-19 | Pharmacia Corporation | Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
| EP2311793A1 (en) | 2004-12-17 | 2011-04-20 | Cipla Ltd. | Crystalline levosalbutamol sulphate (Form II) |
| WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| WO2011068786A2 (en) * | 2009-12-02 | 2011-06-09 | Bridge Pharma, Inc. | Treating xerophthalmia with compounds increasing meibomian gland secretion |
| TN2010000251A1 (fr) | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| TN2010000566A1 (en) | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| WO2014191414A1 (en) * | 2013-05-28 | 2014-12-04 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Syrup formulation of salbutamol |
-
2016
- 2016-06-27 TN TN2016000259A patent/TN2016000259A1/en unknown
-
2017
- 2017-06-27 WO PCT/IB2017/000779 patent/WO2018007864A1/en not_active Ceased
- 2017-06-27 MA MA045457A patent/MA45457A/fr unknown
- 2017-06-27 JP JP2018568424A patent/JP7176960B2/ja not_active Expired - Fee Related
- 2017-06-27 EP EP17745488.1A patent/EP3474836B1/en active Active
- 2017-06-27 CN CN201780052188.6A patent/CN110114066B/zh active Active
- 2017-06-27 US US16/313,425 patent/US11484513B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA45457A (fr) | 2019-05-01 |
| CN110114066A (zh) | 2019-08-09 |
| EP3474836C0 (en) | 2024-01-17 |
| CA3028924A1 (en) | 2018-01-11 |
| US20190160027A1 (en) | 2019-05-30 |
| WO2018007864A1 (en) | 2018-01-11 |
| JP2019524679A (ja) | 2019-09-05 |
| CN110114066B (zh) | 2023-06-27 |
| RU2018146575A3 (enExample) | 2020-09-24 |
| US11484513B2 (en) | 2022-11-01 |
| EP3474836A1 (en) | 2019-05-01 |
| EP3474836B1 (en) | 2024-01-17 |
| JP7176960B2 (ja) | 2022-11-22 |
| RU2018146575A (ru) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011151685A8 (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
| CR10041A (es) | Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares | |
| WO2010100654A3 (en) | A device to directly monitor intra ocular pressure by a person based on pattern and colour changes | |
| MX2018001918A (es) | Aplicación cuantitativa periorbital de farmacos oftalmologicos. | |
| TN2019000112A1 (en) | Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma | |
| MX2019011242A (es) | Farmacos y composiciones para el tratamiento de trastornos oculares. | |
| Cole et al. | Bilateral acute angle-closure glaucoma in a migraine patient receiving topiramate: a case report | |
| WO2019054960A3 (en) | Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging) | |
| CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
| EP4559529A3 (en) | Isocyclosporin a for topical treatment of ocular diseases | |
| Ozek et al. | Hydro cone lens visual performance and impact on quality of life in irregular corneas | |
| Koh et al. | Fundus flavimaculatus and choroidal neovascularization in a young patient with normal electroretinography: case report | |
| Petrachkov et al. | Analysis of surgical treatment results of macular holes in the Samara region | |
| Ozgonul | Chloroquine retinopathy: case report | |
| Kim | Hyaluronic acid | |
| Kiseleva et al. | Blood flow and functional changes in the retina and the optic nerve due to blunt eye trauma | |
| Le Feng et al. | Anatomical and functional outcomes after Densiron 68 heavy silicone oil tamponade for complicated retinal detachment in Chinese eyes | |
| Chanana et al. | Imaging Findings in Bilateral Macular Chorioretinitis Due to Subacute Sclerosing Panencephalitis | |
| Achiron | Acute angle closure glaucoma: case report | |
| 吳東樺 et al. | Tamoxifen Maculopathy-A Case Report | |
| Ha | Ocular hypertension: case report | |
| Sood | Various toxicities: case report | |
| MX2022009136A (es) | Composicion farmaceutica oftalmica y uso de la misma. | |
| Malyshev et al. | Clinical efficacy of vitrectomy when expressed destructive changes in the vitreous | |
| Oga et al. | You're Getting on My Nerves |